Theriva Biologics, Inc.
Here’s whether Theriva Biologics, Inc. (TOVX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.58% over 10 days); RSI 61 — healthy momentum range; 3-month momentum positive (+31.8%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -80.5%. Currently 82.8% off its 52-week high. Score: +1/7.
TOVX is trading below its 200-day MA ($0.31) — a key warning sign the longer-term trend is under pressure. An RSI of 60.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -80.5% compares to +35.1% for SPY (trailed the market by 115.6%). The current 82.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.